Key Moments
Live from Stanford Health AI Week
Stanford OnlineWant to know something specific about what's covered?
We've already dissected every moment. Ask and we will deliver (with timestamps).
Key Moments
AI is rapidly transforming healthcare, but cultural resistance and data infrastructure challenges are hindering its full potential. Experts debate whether AI will solve or exacerbate societal issues.
Key Insights
Diagnostic errors in the US cause or permanently harm an estimated 900,000 Americans annually, presenting a critical area where AI could intervene.
A significant number of patients, particularly those in frontier areas like Idaho, use AI for healthcare information due to issues with access and timely specialist appointments.
Bristol Myers Squibb, a 170-year-old company, has embraced AI by giving 34,000 employees access to a suite of AI tools, facilitating a 'thousand flowers bloom' approach to innovation.
NVIDIA envisions a hybrid approach to AI agents, combining cloud, on-premise, and edge computing to cater to diverse healthcare environments, including Windows-dominated systems.
A key constraint identified is the lack of 'AI data readiness' across many healthcare systems and pharmaceutical companies, impacting the effectiveness of AI agents.
City of Hope has seen record-breaking interventional treatment accruals, with one month exceeding 171 patients, partly due to implementing AI-powered tools like 'Hope Pathways' for trial identification.
The patient empowerment and the diagnostic dilemma
The current state of AI in healthcare is marked by a significant patient empowerment, driven by increased access to information and a growing dissatisfaction with the traditional healthcare system's limitations. Patients increasingly turn to AI for health information and guidance due to issues of access, long wait times for appointments, and feelings of being dismissed by human providers. This trend highlights a 'knowing-doing gap' where valuable medical knowledge exists but is not effectively applied due to systemic constraints, such as limited physician time and burdensome administrative tasks. Diagnostic errors alone are estimated to harm or kill approximately 900,000 Americans annually, presenting a critical area where AI could offer substantial improvements. However, measuring this impact and ensuring AI's role in patient safety remains a key challenge, with calls for patients to be included in research design to focus on outcomes that truly matter to them.
Bridging the divide: Cultural shifts and organizational adoption
A major hurdle in AI adoption within healthcare is cultural resistance and existing biases. Many healthcare professionals and institutions exhibit a 'wait-and-see' attitude or are wary of AI's perceived risks, leading to slow integration. This is compounded by a societal narrative that often focuses on AI's potential harms rather than its benefits. For instance, a viral personal experience with AI for health led to criticism and accusations of 'doctor shopping,' illustrating the deeply entrenched cultural norms that privilege traditional medical authority. Companies like Bristol Myers Squibb are attempting to overcome this by fostering a culture of experimentation, providing widespread access to AI tools, and encouraging 'a thousand flowers to bloom.' However, the pace of AI development far outstrips the pace of human and organizational adaptation, creating a continuous challenge for education and integration. The risk of 'shadow IT' also emerges, where employees bypass official channels to use AI tools, leading to unmanaged risks and duplicated efforts.
The agentic future: Empowering healthcare with localized AI
NVIDIA envisions a future where AI agents are integrated across the healthcare ecosystem through a hybrid approach combining cloud, on-premise, and edge computing. This strategy acknowledges that 95% of global healthcare systems run on Windows, making localized agents that function within familiar environments crucial. These agents can transform scientific instruments into intelligent systems, monitor experiments in real-time, and assist clinicians and nurses in their daily tasks. The concept of an 'inverted triangle' is proposed, with generalist cloud AI APIs at the base, domain-specific agents in the middle for specialized work, and core intellectual property secured at the top. This tiered approach allows for flexibility in leveraging AI, from public cloud services to highly secure on-premise solutions, enabling companies to retain control over proprietary data while benefiting from AI's capabilities.
Data readiness: The foundational challenge for AI in healthcare
A critical bottleneck for effective AI deployment in healthcare is the lack of 'AI data readiness.' Many healthcare systems and pharmaceutical companies possess vast amounts of data, but it is often siloed, unstructured, and not in a format that AI agents can easily process. This necessitates significant effort in data curation, organization, and transformation, a process that is both resource-intensive and time-consuming. Without accessible, well-organized data, AI agents, however sophisticated, are rendered ineffective. Companies are seeking solutions to bring compute closer to the data, enabling faster iteration and development. The challenge extends to ensuring data quality and mitigating bias, as flawed data can lead to biased AI outputs, eroding trust and hindering progress.
Accelerating discovery and patient access through AI
AI holds immense promise for accelerating drug discovery, clinical trial recruitment, and patient access to novel therapies. At City of Hope, AI-powered tools like 'Hope Pathways' have significantly improved clinical trial accrual, demonstrating the potential for technology to enhance operational efficiencies. By surfacing relevant trial information quickly and visually, these tools empower frontline providers to connect patients with appropriate studies. This is crucial, as many patients, particularly those with rare cancers or in community practices, lack access to trials available at major academic centers. AI can help democratize access by overcoming information silos and empowering providers to identify eligible patients more effectively, potentially saving lives by bridging the gap between discovery and patient care.
Rethinking R&D and funding in a rapidly changing scientific landscape
The exponential pace of AI development presents a challenge to traditional scientific research cadences, including the lengthy processes for peer review and grant funding. NIH and NSF award cycles, for instance, can take 18 months, by which time the underlying AI models used in studies may be obsolete. This necessitates a re-evaluation of how scientific research is conducted and funded, encouraging more agile and iterative approaches. While AI can accelerate information retrieval and analysis, the rigor of scientific review remains essential. Experts advocate for adapting the fundamental structures of R&D to match the speed of contemporary technological advancement, ensuring that innovation is not stifled by outdated processes. The investment in research must be re-envisioned to meet future needs, not just replicate past architectures.
The public narrative and the trust deficit in AI
A significant disconnect exists between the techno-optimism within the AI community and the broader public's perception. Recent polls indicate that a majority of Americans believe AI will do more harm than good, a sentiment exacerbated by concerns over job displacement, misinformation, and the ethics of AI deployment. While healthcare is seen as a more regulated area with greater potential for responsible AI integration, other sectors have already experienced significant negative impacts, such as the proliferation of deepfake nudes. Addressing this trust deficit requires more than just explaining how AI works; it demands tangible evidence of positive outcomes and a commitment to responsible development. The 'great sorting' of roles and responsibilities in the economy is underway, and AI is a catalyst, prompting crucial conversations about workforce adaptation, ethical deployment, and societal benefit.
Addressing systemic constraints: Resources, infrastructure, and broader societal issues
Ultimately, the greatest constraint hindering AI's transformative potential in healthcare, and society more broadly, is a multifaceted resource issue. This includes not only the financial and computational resources but also the time and expertise needed to develop, implement, and manage AI effectively. Deep-seated issues like the poor state of data infrastructure in healthcare, the erosion of trust in scientific institutions, and the impact of societal polarization create significant barriers. While AI can help bridge the 'knowing-doing gap' in healthcare and accelerate discovery, it cannot solve fundamental issues like health inequality or political division on its own. The path forward requires not only technological advancement but also a societal commitment to building robust infrastructure, fostering trust, and ensuring that AI is deployed equitably to benefit all.
Mentioned in This Episode
●Software & Apps
●Companies
●Organizations
●People Referenced
Common Questions
Currently, there is little research on patient use of AI. To measure its impact, we need to design research questions with patients at the table, focusing on outcomes that matter to them. Vendors like OpenAI have some data, but formal research involving patient input is crucial to understand the positive effects.
Topics
Mentioned in this video
Mentioned in the context of a debate about the impact of AI on patient understanding and access to information.
Vice President of Healthcare at NVIDIA, joining the discussion to share insights on on-premise AI, edge computing, and agentic systems in healthcare.
NVIDIA CEO, quoted as saying, 'we just reinvented the PC for the first time in 40 years,' in relation to empowering professionals with AI capabilities.
Director of the FDA's Oncology Center of Excellence, mentioned in the context of expanding clinical trial eligibility criteria.
Physician-in-Chief at City of Hope, who shares his experiences and insights on AI's impact on clinical trials, patient care, and research.
Mentioned for his work with Sayash Kapoor on 'AI as normal technology,' which offers a grounded perspective in the context of overhyped AI environments.
Mentioned for his work with Arvind Narayanan on 'AI as normal technology,' providing a realistic view of AI's integration.
Mentioned as an organization whose data insights on healthcare chats showed correlation with access to care. The speaker also envisioned a partnership with OpenAI for solving diagnostic problems.
Mentioned as a social media channel where a speaker was criticized for challenging a doctor with AI-derived information.
The speaker's large organization that is making significant investments in AI for drug development and manufacturing, illustrating cultural challenges and successes in AI adoption.
Mentioned by the host as an organization where they previously worked and met with large healthcare organizations, observing varied enthusiasm for AI.
The company Kimberly Powell represents, discussed for its open-source strategy, open models (Cosmos, Neotron, Bionmo), and hardware platforms enabling AI in healthcare, particularly for on-premise solutions.
Mentioned as a company that announced an 'AI factory' to provide scientists with access to modern scientific instruments, deploying AI locally to protect core IP.
A company mentioned that is helping enterprises get their data ready for AI and agents, as agents are useless without data.
A company mentioned that is helping enterprises get their data ready for AI and agents.
Mentioned as a company working to take all lab data and integrate it into an ontology for scientific workflows, addressing the challenge of data readiness for AI.
Cited as a company driving enterprise AI adoption in healthcare by offering solutions that seamlessly integrate, allowing professionals to regain time.
Partnered with the University of Texas in published work identifying gaps in cardiovascular care using AI.
Used by a speaker to envision a partnership for solving diagnostic problems. Also mentioned as a tool used by a doctor for patient care insights.
NVIDIA's world model framework, mentioned for its multimodal and reasoning capabilities in agentic systems.
NVIDIA's biology language model, part of their open models collection at the frontier, meant for post-training with domain-specific data.
Cited as a company driving the faster deployment of enterprise AI in healthcare by solving acute problems with zero barrier to entry, giving physicians more time back.
Mentioned as a breakthrough that addressed traditional protein folding problems, opening opportunities for AI in drug development.
Mentioned as an organization that the speaker's group is working with to change data collection mechanisms for patient-reported diagnostic errors.
Mentioned as a company providing up-to-date medical knowledge, designed to read, think, and communicate like a trained physician, and connect patients to clinical trials.
National Cancer Institute, mentioned in relation to the speaker chairing its central IRB for patient safety and drug approvals.
Food and Drug Administration, discussed in the context of drug approvals and the potential for AI to lower the bar for new drugs while maintaining safety.
A cancer research and treatment center where Ed Kim is Physician-in-Chief. Discussed for its programs in integrative oncology and clinical trials, and its expansion to multiple campuses.
National Institutes of Health, mentioned as a bedrock institution for publicly funded research, whose funding is now facing challenges due to national polarization.
National Science Foundation, highlighted as a fundamental institution for federal research that is facing disruption from national political issues.
Centers for Disease Control and Prevention, referenced as a vital public health organization whose trust and funding are under threat.
Referenced for a poll indicating significant public concern about AI, with 50% of Americans believing it will do more harm than good.
Mentioned as a partner in published work with Anthropic on identifying gaps in cardiovascular care using AI.
More from Stanford Online
View all 83 summaries
35 minStanford Robotics Seminar ENGR319 | Spring 2026 | Towards Trustworthy Autonomy
58 minStanford CS153 Frontier Systems | Building the Frontier Ecosystem
50 minStanford MS&E435 Economics of the AI Supercycle | Spring 2026 | Applications, Coding AI
50 minStanford MS&E435 Economics of the AI Supercycle | Spring 2026 | Building AI Factories
Ask anything from this episode.
Save it, chat with it, and connect it to Claude or ChatGPT. Get cited answers from the actual content — and build your own knowledge base of every podcast and video you care about.
Get Started Free